Iovance Biotherapeutics to Participate in Upcoming Conferences in June

May 31, 2019

SAN CARLOS, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to participate in the following conferences in June:

- **Showcasing Greater Philadelphia’s Life Sciences & Innovation Assets at BIO 2019** in Philadelphia, June 3, 2019
  Location: Comcast Technology Center
  Date/Time: Monday, June 3, 2019, from 3:30 p.m. - 6:30 p.m. EDT

- **Jefferies 2019 Healthcare Conference** in New York, June 4-7, 2019
  Corporate overview
  Location: Grand Hyatt New York
  Date/Time: Wednesday, June 5, at 11:30 a.m. EDT
  A live and archived webcast of the presentation will be available by visiting the Investors section of the Iovance Biotherapeutics website at [http://ir.iovance.com](http://ir.iovance.com).
  Session: Best of ASCO Panel
  Location: Grand Hyatt New York
  Date/Time: Thursday, June 6, from 12:15 p.m. - 1:15 p.m. EDT

- **24th Congress of the European Hematology Association (EHA)** in Amsterdam, June 13-16, 2019
  Poster: Iovance Peripheral Blood Lymphocytes (PBL): A Potential Cell Therapy Strategy For The Treatment Of Chronic Lymphocytic Leukemia
  Authors: Lavakumar Karyampudi et al.
  Session: Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research
  Abstract Number: PF447
  Location: RAI Amsterdam
  Date/Time: Friday, June 14, from 5:30 p.m. - 7:00 p.m. CEST

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics intends to commercialize lifileukel, an autologous cell therapy product using TIL technology that amplifies the body's own immune response to eradicate solid tumors or attack blood cancers. The company is currently conducting the pivotal study innovaTIL-01 in patients with metastatic melanoma. In addition, the company’s TIL therapies are being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including cervical, head and neck, and non-small cell lung cancer. For more information, please visit [www.iovance.com](http://www.iovance.com).

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”). We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. The forward-looking statements include, but are not limited to, risks and uncertainties relating to the success, timing, projected enrollment, manufacturing and production capabilities, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates (including both Company-sponsored and collaborator-sponsored trials in both the U.S. and Europe), such as statements regarding the timing of initiation and completion of these trials; the timing of and our ability to obtain and maintain FDA or other regulatory authority approval of, or other action with respect to, our product candidates, including those product candidates that have been granted breakthrough therapy designation (“BTD”) or regenerative medicine advanced therapy designation (“RMAT”) by the FDA; the strength of the Company’s product pipeline; the successful implementation of the Company’s research and development programs and collaborations; the Company’s ability to obtain tax incentives and credits; the success of the Company’s manufacturing, license or development agreements; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business, including, without limitation; the preliminary clinical results, including efficacy and safety results, from ongoing Phase 2 studies may not be reflected in the final analyses of these trials, including new cohorts within these trials, and may not be supportive of product approval; the FDA or other regulatory authorities may potentially delay the timing of their approval of, or other action with respect to, the Company’s product candidates; the Company’s ability to address FDA or other regulatory authority requirements relating to its clinical programs and registrational plans, such requirements including, but not limited to, clinical and safety requirements as well as manufacturing and control requirements; risks related to the Company’s ability to maintain and benefit from accelerated FDA review designations, including BTD and RMAT, which may not ultimately result in a
faster development process or review of the Company’s product candidates (and which may later be rescinded by the FDA if such product candidates no longer meet the conditions for qualification for the program), and does not in any way assure approval of such product candidates by the FDA or the ability of the Company to obtain FDA approval in time to benefit from commercial opportunities; and the ability of the Company to manufacture its therapies using third party manufacturers. A further list and description of the Company's risks, uncertainties and other factors can be found in the Company’s most recent Annual Report on Form 10-K and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.iovance.com. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investor Relations Contacts:
Annie Chang
Solebury Trout
646-378-2972
achang@troutgroup.com

Chad Rubin
Solebury Trout
646-378-2947
crubin@troutgroup.com

Media Relations Contact:
Rich Allan
Solebury Trout
646-378-2958
ralan@troutgroup.com

Iovance Biotherapeutics, Inc.